Tuberculosis; TB; drug-sensitive tuberculosis; DS-TB; MDR-TB; multidrug-resistant TB; regimen development; pretomanid, moxifloxacin, pyrazinamide; ethambutol; HRZE, phase 3 clinical trial; PaMZ